June 5, 2012
Malignant hyperthermia: A crisis response plan
Malignant hyperthermia (MH) is a genetic skeletal muscle disorder that is incited by anesthesia drugs including succinlycholine and inhaled anesthetic agents (Gurunluoglu et al, 2009; Hopkins, 2011; Kim et al, 2011). The disorder is particularly dangerous because it rapidly develops into a hypermetabolic state resulting in hyperpyrexia, tachycardia, and intense and unrelenting muscle contraction as well as alterations in electrolyte and acid-base balance (Kim et al, 2011).
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement